Assessment of a feed additive consisting of RRR‐alpha‐tocopheryl acetate (vitamin E) for all animal species for the renewal of its authorisation (Specialty Ingredients (Europe) B.V. and Vitae Caps S.A.)

• Main Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fašmon Durjava, Maryline Kouba, Marta López‐Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Georges Bories, Jürgen Gropp, Montserrat Anguita, Jaume Galobart, Orsolya Holczknecht, Paola Manini, Jordi Tarrés‐Call, Elisa Pettenati, Maria Vittoria Vettori, Fabiola Pizzo
• Format: Article
• Language: English
• Published: Wiley 2021-04-01
• Series: EFSA Journal
• Subjects: RRR‐alpha tocopheryl acetate; vitamin E; renewal; nutritional additive; vitamins and pro‐vitamins; feed
• Online Access: https://doi.org/10.2903/j.efsa.2021.6532

Abstract Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of RRR‐alpha‐tocopheryl acetate (vitamin E) as a feed additive for all animal species. The applicant provided data demonstrating that the additive currently in the market complies with the conditions of authorisation. The FEEDAP Panel confirms that the use of RRR‐alpha‐tocopheryl acetate under the current authorised conditions of use is safe for the target species, the consumers and the environment. No concern for user safety is expected from the use of the active substance; however, due to the lack of information, the FEEDAP Panel is not able to conclude on its skin sensitisation potential. To draw conclusions on the safety for the user of the final formulated additives, specific studies would be required. There is no need to assess the efficacy of RRR‐alpha‐tocopheryl acetate in the context of the renewal of the authorisation.